<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1808222508
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RIBOMUSTIN 100 mg powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BENDAMUSTINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5196.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CENEXI-LABORATORIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CENEXI-LABORATORIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASTELLAS PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ribomustin is a medicine which is used for the treatment of certain types of cancer (cytotoxic medicine).</p><p>&nbsp;</p><p>Ribomustin is used alone (monotherapy) or in combination with other medicines for the treatment of the following forms of cancer:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic lymphocytic leukaemia in cases where fludarabine combination chemotherapy is not appropriate for you,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-Hodgkin lymphomas, which had not, or only shortly, responded to prior rituximab treatment,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multiple myeloma in cases where thalidomide or bortezomib containing therapy is not appropriate for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp; Do not use Ribomustin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are hypersensitive (allergic) to the active substance bendamustine hydrochloride or any of the other ingredients of Ribomustin;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; while breast-feeding;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver dysfunction (damage to the functional cells of the liver);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have yellowing of the skin or whites of the eyes caused by liver or blood problems (jaundice);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severely disturbed bone marrow function (bone marrow depression) and serious</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>changes in your number of white blood cells and platelets in the blood (white blood cells and/or thrombocyte values dropped to &lt; 3,000/&micro;l or &lt; 75,000/&micro;l, respectively.);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had major surgical operations less than 30 days before starting treatment;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an infection, especially one accompanied by a reduction in white blood cells (leucocytopenia);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with yellow fever vaccines.</p><p>&nbsp;</p><p>Take special care with Ribomustin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of reduced capability of the bone marrow to replace blood cells. You should have your number of white blood cells and platelets in the blood checked before starting treatment with Ribomustin, before each subsequent course of treatment and in the intervals between courses of treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of infections. You should contact your doctor if you have signs of infection, including fever or lung symptoms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of reactions on your skin during treatment with Ribomustin. The reactions may increase in severity.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in cases of existing heart disease (e.g. heart attack, chest pain, severely disturbed heart rhythms).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case you notice any pain in your side, blood in your urine or reduced amount of urine. When your disease is very severe, your body may not be able to clear all the waste products from the dying cancer cells. This is called tumour lysis syndrome and can cause kidney failure and heart problems within 48 hours of the first dose of Ribomustin. Your doctor will be aware of this and may give you other medicines to help prevent it.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of severe allergic or hypersensitivity reactions. You should pay attention to infusion reactions after your first cycle of therapy.</p><p>&nbsp;</p><p>Men receiving treatment with Ribomustin are advised not to conceive a child during treatment and for up to 6 months afterwards. Before starting treatment, you should seek advice on storing sperm because of the possibility of permanent infertility.</p><p>&nbsp;</p><p>Unintentional injection into the tissue outside blood vessels (extravasal injection) should be stopped immediately. The needle should be removed after a short aspiration. Thereafter the affected area of tissue should be cooled. The arm should be elevated. Additional treatments like the use of corticosteroids are not of clear benefit (see section 4).</p><p>&nbsp;</p><p>Using other medicines</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>If Ribomustin is used in combination with medicines which inhibit the formation of blood in the bone marrow, the effect on the bone marrow may be intensified.</p><p>&nbsp;</p><p>If Ribomustin is used in combination with medicines which alter you immune response, this effect may be intensified.</p><p>&nbsp;</p><p>Cytostatic medicines may diminish the effectiveness of live-virus vaccination. Additionally cytostatic medicines increase the risk of an infection after vaccination with live vaccines (e.g. viral vaccination).</p><p>&nbsp;</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>Pregnancy</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ribomustin&trade; can cause fetal harm when administered to a pregnant woman. Single intraperitoneal doses of bendamustine from 210 mg/m2 (70 mg/kg) in mice administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (exencephaly, cleft palates, accessory&nbsp; rib, and spinal deformities) and decreased fetal body weights. This dose did not appear to be maternally toxic and lower doses were not evaluated. Repeat intraperitoneal dosing in mice on gestation days 7-11 resulted in an increase in resorptions from 75 mg/m2 (25 mg/kg) and an increase in abnormalities from</p><p>112.5 mg/m2 (37.5 mg/kg) similar to those seen after a single intraperitoneal administration. Single intraperitoneal doses of bendamustine from 120 mg/m2 (20 mg/kg) in rats administered on gestation days 4, 7, 9, 11, or 13 caused embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. A significant increase in external [effect on tail, head, and herniation of external organs (exomphalos)] and internal (hydronephrosis and hydrocephalus) malformations were seen in dosed rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p><p>&nbsp;</p><p>Breast-feeding</p><p>Ribomustin must not be administered during breast feeding. If treatment with Ribomustin is necessary during lactation you must discontinue breast-feeding.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>No studies on the effects on the ability to drive and to use machines have been performed.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not drive or operate machines if you experience side effects, such as dizziness or lack of coordination.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ribomustin is administered into a vein over 30-60 minutes in various dosages, either alone (monotherapy) or in combination with other medicines.</p><p>Treatment should not be started if your white blood cells (leukocytes) have fallen to counts below 3,000 cells/&micro;l and/or your blood platelets have fallen to counts below 75,000 cells/&micro;l.</p><p>Your doctor will determine these values at regular intervals.</p><p>&nbsp;</p><p>Chronic lymphocytic leukaemia</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Ribomustin 100 mg per square metre of your body surface area (based on your height and weight)</p></td><td style="vertical-align:top"><p>on Days 1+2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Repeat the cycle after 4 weeks up to 6 times</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Non-Hodgkin lymphomas</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Ribomustin 120 mg per square metre of your body surface area (based on your height and weight)</p></td><td style="vertical-align:top"><p>on Days 1 + 2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Repeat the cycle after 3 weeks at least 6 times</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Multiple myeloma</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Ribomustin 120 - 150 mg per square meter of your body surface area (based on your height and weight)</p></td><td style="vertical-align:top"><p>on Days 1 + 2</p></td></tr><tr><td style="vertical-align:top"><p>Prednisone 60 mg per square metre of your body surface area (based on your height and weight) by injection or orally.</p></td><td style="vertical-align:top"><p>on Days 1 - 4</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Repeat the cycle after 4 weeks at least 3 times</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Treatment should be terminated if white blood cell (leukocyte) and/or platelet values dropped to &lt; 3,000/&micro;l or &lt; 75,000/&micro;l, respectively. Treatment can be continued after white blood cell values have increased to &gt; 4,000/&micro;l and platelet values to &gt; 100,000/&micro;l.</p><p><u>Impaired liver or kidney function </u></p><p>Dependent on the degree of impairment of your liver function it may be necessary to adjust your dose (by 30% in case of moderate liver dysfunction). No dose adjustment is necessary in case of impairment of kidney function. Your attending doctor will decide whether a dosage adjustment is necessary.</p><p><u>How it is administered </u></p><p>Treatment with Ribomustin should be undertaken only by doctors experienced in tumour therapy. Your doctor will give you the exact dose of Ribomustin and use the necessary precautions.</p><p>Your attending doctor will administer the solution for infusion after preparation as prescribed. The solution is administered into a vein as a short-term infusion over 30 - 60 minutes.</p><p><u>Duration of use </u></p><p>There is no time limit laid down as a general rule for treatment with Ribomustin. Duration of treatment depends on disease and response to treatment.</p><p>&nbsp;</p><p>If you are at all worried or have any questions regarding treatment with Ribomustin, please speak to your doctor or nurse.</p><p>&nbsp;</p><p>If you forget to use Ribomustin</p><p>If a dose of Ribomustin has been forgotten, your doctor will usually retain the normal dosage schedule.</p><p>&nbsp;</p><p>If you stop using of Ribomustin</p><p>The doctor treating you will decide whether to interrupt the treatment or to change over to a different preparation.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Ribomustin can cause side-effects, although not everybody gets them. The following definitions of frequency are used when assessing side-effects:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>affects more than 1 user in 10</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>affects 1 to 10 users in 100</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>affects 1 to 10 users in 1,000</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>affects 1 to 10 users in 10,000</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>affects less than 1 user in 10,000</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>frequency cannot be estimated from the available data</p></td></tr></tbody></table><p>&nbsp;</p><p>Tissue changes (necrosis) have been observed very rarely following unintentional injection into the tissue outside blood vessels (extravascular). A burning sensation where the infusion needle is inserted may be a sign for administration outside the blood vessels. The consequence of administration in this way can be pain and poorly healing skin defects.</p><p>The dose-limiting side-effect of Ribomustin is impaired bone-marrow function, which usually returns to normal after treatment. Suppressed bone marrow function increases the risk of infection.</p><p>&nbsp;</p><p>Very common:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&bull;&nbsp; Low counts of white blood cells (leukocytopenia)</p><p>&bull;&nbsp; Decrease in the red pigment of the blood (haemoglobin)</p><p>&bull;&nbsp; Low counts of platelets (thrombocytopenia)</p></td><td style="vertical-align:top"><p>&bull;&nbsp; Infections</p><p>&bull;&nbsp; Feeling sick (nausea)</p><p>&bull;&nbsp; Vomiting</p><p>&bull;&nbsp; Mucosal inflammation</p></td><td style="vertical-align:top"><p>&bull;&nbsp; Increased blood level of creatinine</p><p>&bull;&nbsp; Increased blood level of urea</p><p>&bull;&nbsp; Fever</p><p>&bull;&nbsp; Fatigue</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Common:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&bull;&nbsp; Bleeding (haemorrhage)</p><p>&bull;&nbsp; Disturbed metabolism caused by dying cancer cells releasing their contents into the blood stream</p><p>&bull;&nbsp; Reduction in red blood cells which can make the skin pale and cause weakness or breathlessness (anaemia)</p><p>&bull;&nbsp; Low counts of neutrophils (neutropenia)</p><p>&bull;&nbsp; Hypersensitivity reactions such as allergic inflammation of the skin (dermatitis), nettle rash (urticaria)</p><p>&bull;&nbsp; A rise in liver enzymes AST/ALT</p><p>&bull;&nbsp; A rise in the enzyme alkaline phosphatase</p><p>&bull;&nbsp; A rise in bile pigment</p></td><td style="vertical-align:top"><p>&bull;&nbsp; Low potassium blood levels</p><p>&bull;&nbsp; Disturbed function (dysfunction) of the heart</p><p>&bull;&nbsp; Disturbed heart rhythms (arrhythmia)</p><p>&bull;&nbsp; Low or high blood pressure (hypotension or hypertension)</p><p>&bull;&nbsp; Disturbed lung function</p><p>&bull;&nbsp; Diarrhoea</p><p>&bull;&nbsp; Constipation</p><p>&bull;&nbsp; Sore mouth (Stomatitis)</p><p>&bull;&nbsp; Loss of appetite</p></td><td style="vertical-align:top"><p>&bull;&nbsp; Hair loss</p><p>&bull;&nbsp; Skin changes</p><p>&bull;&nbsp; Missed periods (amenorrhoea)</p><p>&bull;&nbsp; Pain</p><p>&bull;&nbsp; Insomnia</p><p>&bull;&nbsp; Chills</p><p>&bull;&nbsp; Dehydration</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Uncommon:</strong></p><p>&bull;&nbsp; Accumulation of fluid in the heart sac (escape of fluid into the pericardial space)</p><p>Rare:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&bull;&nbsp; Infection of the blood (sepsis)</p><p>&bull;&nbsp; Severe allergic hypersensitivity reactions (anaphylactic reactions)</p></td><td style="vertical-align:top"><p>&bull;&nbsp; Signs similar to anaphylactic reactions (anaphylactoid reactions)</p><p>&bull;&nbsp; Drowsiness</p><p>&bull;&nbsp; Loss of voice (aphonia)</p><p>&bull;&nbsp; Acute circulatory collapse</p></td><td style="vertical-align:top"><p>&bull;&nbsp; Reddening of the skin (erythema)</p><p>&bull;&nbsp; Inflammation of the skin (dermatitis)</p><p>&bull;&nbsp; Itching (pruritus)</p><p>&bull;&nbsp; Skin rash (macular exanthema)</p><p>&bull;&nbsp; Excessive sweating (hyperhidrosis)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Very rare:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&bull;&nbsp; Primary atypical inflammation of the lungs (pneumonia)</p><p>&bull;&nbsp; Break-down of red blood cell</p><p>&bull;&nbsp; Rapid decrease in blood pressure sometimes with skin reactions or rash (anaphylactic shock)</p><p>&bull;&nbsp; Disturbed sense of taste</p><p>&bull;&nbsp; Altered sensations (paraesthesia)</p><p>&bull;&nbsp; Malaise and pain in the limbs (peripheral neuropathy)</p><p>&bull;&nbsp; Disease of the nervous system (anticholinergic syndrome)</p></td><td style="vertical-align:top"><p>&bull;&nbsp; Neurological disorders</p><p>&bull;&nbsp; Lack of coordination (ataxia)</p><p>&bull;&nbsp; Inflammation of the brain (encephalitis)</p><p>&bull;&nbsp; Increased heart rate (tachycardia)</p><p>&bull;&nbsp; Heart attack, chest pain (myocardial infarct)</p><p>&bull;&nbsp; Heart failure</p></td><td style="vertical-align:top"><p>&bull;&nbsp; Inflammation of the veins (phlebitis)</p><p>&bull;&nbsp; Formation of tissue in the lungs (fibrosis of the lungs)</p><p>&bull;&nbsp; Bleeding inflammation of the gullet (haemorrhagic oesophagitis)</p><p>&bull;&nbsp; Bleeding of stomach or gut</p><p>&bull;&nbsp; Infertility</p><p>&bull;&nbsp; Multiple organ failure</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>There have been reports of secondary tumours (myelodysplastic syndrome, AML, bronchial carcinoma) following treatment with Ribomustin. No clear relationship with Ribomustin could be</p><p>determined.</p><p>A small number of cases of severe skin reactions ( Stevens-Johnson Syndrome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and Toxic Epidermal Necrolysis) have been&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reported. The relationship with Ribomustin is unclear.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>National Pharmacovigilance and Drug Safety Center (NPC) Vigilance and crisis management :</p><p>+9662038222 Ext : 2353 , 2354 , 2340 , 2317 , 2334 , 2356 .</p><p>- Fax: +966-11-205-7662</p><p>- Toll-free: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children. Store below 30&deg;C.</p><p>&nbsp;</p><p>Do not use Ribomustin after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month.</p><p>Keep the container in the outer carton to protect the content from light.</p><p>Note on shelf-life after opening or preparing the solution</p><p>Solutions for infusions prepared according to the directions listed at the end of this leaflet are stable in polyethylene bags at room temperature / 60% relative humidity for 3.5 hours, and in a refrigerator they are stable for 2 days. Ribomustin contains no preservatives. The solutions should not therefore be used after these lengths of time.</p><p>It is the responsibility of the user to maintain aseptic conditions.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is bendamustine hydrochloride.</p><p>1 vial contains 25 mg of bendamustin<u>e </u>hydrochloride 1 vial contains 100 mg of bendamustin<u>e </u>hydrochloride</p><p>After reconstitution 1 ml of the concentrate contains 2.5 mg bendamustine hydrochloride.</p><p>The other ingredient is Mannitol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Brown glass vials with rubber stopper and an aluminium flip-off cap.
The powder appears white and crystalline.
Ribomustin is available in packs containing
5, 10 and 20 injection vials with 25 mg of bendamustine hydrochloride and
5 injection vials with 100 mg of bendamustine hydrochloride. Not all pack sizes may be available.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Astellas Pharma GmbH Postfach 50 01 66</p><p>D-80971 M&uuml;nchen</p><p><strong>Manufacturer of the final product</strong></p><p>Cenexi-Thissen Laboratories SA Rue de la Papyr&eacute;e 2-6,</p><p>B-1420 Braine-L&acute;Alleud Belgium</p><p>Or</p><p>Oncotec Pharma Produktion GmbH Am Pharmapark</p><p>06861 Dessau-Ro&szlig;lau Germany</p><p><strong>Manufacturer responsible for batch release</strong></p><p>Haupt Pharma Wolfratshausen GmbH Pfaffenrieder Stra&szlig;e 5</p><p>82515 Wolfratshausen Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in November 2013.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ريبوماستين عبارة عن دواء يُستخدم لعالج أنواع معينة من السرطان&nbsp;(دواء مسمم&nbsp;للخاليا.)</p><p dir="RTL">يُستخدم ريبوماسيتن بمفرده&nbsp;(عالج&nbsp;أحادي)أو&nbsp;بالتزامن مع أدوية أخرى لعالج أشكال السرطان التالية:</p><p dir="RTL">- &nbsp;ابيضاض الخاليا اللمفاوية المزمن في الحاالت التي ال يكون فيها العالج الكيميائي بالتزامن مع الفلودارابين مالئ ًما بالنسبة لك،</p><p dir="RTL">المسبق أو استجابت له لفترة قصيرة</p><p dir="RTL">-&nbsp; األورام اللمفاوية من األنواع األخرى بخالف هودجكن التي لم تستجب لعالج ريتوكسيماب</p><p dir="RTL">فقط.</p><p dir="RTL">- &nbsp;ورم خاليا نخاع العظام الخبيث المتعدد في الحاالت التي يكون فيها العالج المحتوي على الثاليدوميد أو البورتيزوميب غير مالئم</p><p dir="RTL">بالنسبة لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;ال</strong><strong> يجب استخدام ريبوماستين في الحاالت التالية</strong></p><p dir="RTL">- &nbsp;إذا كنت شديد الحساسية للمادة الفعالة هيدروكلوريد بينداموستين أو أي من مكونات ريبوماستين األخرى؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أثناء الرضاعة الطبيعية؛</p><p dir="RTL">-&nbsp; إذا كنت تعاني من خلل حاد في وظائف الكبد (تلف الخاليا الوظيفية للكبد)؛</p><p dir="RTL">- &nbsp;إذا كنت تعاني من اصفرار الجلد أو بياض العينين الناتج عن مشكالت في الكبد أو الدم (الصفراء)؛</p><p dir="RTL">وتغيرات شديدة في عدد كرات الدم البيضاء</p><p dir="RTL">(قصور في النخاع العظمي)</p><p dir="RTL">- &nbsp;إذا كنت تعاني من خلل حاد في وظيفة النخاع العظمي</p><p dir="RTL"><em>/</em>75,000ميكروليتر</p><p dir="RTL"><em>/</em>3,000ميكروليتر أو &lt;</p><p dir="RTL">(انخفاض قيم خاليا الدم البيضاء و/أو الصفيحات إلى &lt;</p><p dir="RTL">والصفيحات الدموية</p><p>.ًما يو &nbsp;30</p><p dir="RTL">على التوالي).؛</p><p dir="RTL">- &nbsp;إذا كنت قد خضعت لعملية جراحية كبرى قبل بدء العالج بأقل من</p><p>&nbsp;</p><p dir="RTL">(قلة كرات الدم البيضاء)؛</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;إذا كنت مصا&nbsp;ًبا&nbsp;بعدوى&nbsp;وخاصة&nbsp;إذا كانت مصحوبة بانخفاض في عدد كرات الدم البيضاء</p><p dir="RTL">- بالتزامن مع أمصال الحمى الصفراء.</p><p>&nbsp;</p><p>يجب توخي الحذر الشديد عند استعمال ريبوماستين في الحاالت التالية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; في حالة انخفاض قدرة النخاع العظمي على استبدال الخاليا الدموية. يجب عد كرات الدم البيضاء والصفيحات الدموية لديك قبل</p><p dir="RTL">بدء العالج باستخدام ريبوماستين قبل كل برنامج من برامج العالج المتتالية وفي الفترات الزمنية الفاصلة بين برامج العالج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; في حالة العدوى. يجب االتصال بطبيبك إذا كانت لديك أية عالمات لحدوث عدوى بما في ذلك أعراض الحمى أو عدوى الرئة.</p><p dir="RTL">-&nbsp; في حالة ظهور تفاعالت على الجلد أثناء العالج باستخدام ريبوماستين. يمكن أن تزداد التفاعالت حدةً.</p><p dir="RTL">-&nbsp; في حاالت مرض القلب (مثل النوبة القلبية أو ألم الصدر أو الحاالت الشديدة لعدم انتظام ضربات القلب.)</p><p dir="RTL">-&nbsp; إذا الحظت أي ألم في جانبك أو د ًما في البول أو انخفاضا في كمية البول. عندما يزداد المرض شدة، قد ال يمكن للجسم التخلص</p><p dir="RTL">من جميع الفضالت الناتجة عن خاليا السرطان الميتة. وهو ما &nbsp;طلق عليه متالزمة انحالل الورم ويمكن أن تتسبب في الفشل</p><p>&nbsp;</p><p dir="RTL">ساعة من جرعة ريبوماستين األولى.طبيبك على علم بهذا وقد يعطيك أدوية أخرى للمساعدة</p><p>&nbsp;</p><p dir="RTL">الكلوي ومشكالت قلبية خالل 48</p><p dir="RTL">في الوقاية من هذا.</p><p>&nbsp;</p><p dir="RTL">-&nbsp; في حالة تفاعالت الحساسية الحادة أو الحساسية المفرطة.يجب االنتباه إلى تفاعالت التسريب الوريدي بعد خضوعك لدورة العالج</p><p dir="RTL">األولى.</p><p>&nbsp;</p><p dir="RTL">ُينصح&nbsp;الرجال الذين يتناولون عالج ريبوماستين بعدم التفكير في إنجاب األطفال أثناء العالج ولمدة&nbsp;6&nbsp;&nbsp;أشهر بعده.&nbsp;قبل بدء العالج،</p><p dir="RTL">يجب االستشارة بخصوص تخزين الحيوانات المنوية بسبب إمكانية اإلصابة بالعقم وعدم القدرة على اإلنجاب بشكل دائم.</p><p>&nbsp;</p><p dir="RTL">يجب على الفور إيقاف الحقن عن طريق الخطأ في النسيج خارج األوعية الدموية. يجب إزالة اإلبرة بعد بزل قصير. وبعدها يجب تبريد منطقة النسيج المصابة. يجب رفع الذراع. من غير الواضح ما إذا كانت للعالجات األخرى مثل استخدام الكورتيكوستيرويدات</p><p dir="RTL">فوائد (انظر القسم .)4</p><p>&nbsp;</p><p>االستخدام مع أدوية أخرى</p><p dir="RTL">يُرجى&nbsp;إخطار الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى أو تكون قد تناولتها مؤخ&nbsp;ًرا،&nbsp;بما&nbsp;في ذلك األدوية المستخدمة دون</p><p dir="RTL">وصفة طبية.</p><p>&nbsp;</p><p dir="RTL">عند استخدام ريبوماستين بالتزامن مع األدوية التي تثبط تكون الدم في النخاع العظمي، فقد يكون التأثير على النخاع العظمي شديدًا.</p><p>&nbsp;</p><p dir="RTL">عند استخدام ريبوماستين بالتزامن مع األدوية التي تغ &nbsp;ِّير من االستجابة المناعية،</p><p dir="RTL">فقد يكون هذا التأثير شديدًا.</p><p>&nbsp;</p><p dir="RTL">قد تقلل األدوية المثبطة للخاليا من فعالية التطعيم بالفيروسات الحية. باإلضافة إلى ذلك، تزيد األدوية المثبطة للخاليا من خطورة</p><p dir="RTL">العدوى بعد التطعيم باألمصال الحية (التطعيم الفيروسي.)</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">الحمل من الممكن ان يسبب مستحضر{ريبوماستين} ضررا للجنين إذا عولجت به امرأة حامل&quot;.إذا استخدمت امرأة حامل هذا الدواء كعالج خالل فترة الحمل, أو أصبحت المريضة حامال وهي ال تزال تحت العالج بهذا الدواء فإنه يتحتم إبالغها بالمخاطر المحتملة على جنينها</p><p dir="RTL">نتيجة ذلك.</p><p dir="RTL">ومن الممكن ان يتسبب دواء ريبوماستين Ribomustin في إحداث ضرر بالجنين إذا عولجت به إمراة حامل. أما نتائج تجارب على الفئران تم حقنها بجرعة واحدة داخل الصفاق من مشتق البندامستين Bendamustine بنسبة 210مليجرامm2/ 70(&nbsp;مليجرام)kg/ وذلك أثناء تخلق أعضاء الجنين, فقد أظهرت زيادة في االرتشاح, تشوهات في الهيكل العظمي واألحشاء (أختراج</p><p dir="RTL">الدماغ , الحنك المشقوق, نشوء ضلوع إضافية, تشوهات في العمود الفقري) ونقص في وزن جسم الجنين.</p><p>&nbsp;</p><p dir="RTL">ولم تبن النتائج تعرض األم الحامل أ لي تسمم. أيضا لم يتم تقييم الجرعة المخفضة. أما نتيجة حقن الفئران بجرعات متكررة من الدواء داخل الصفاق أثناء أيام الحمل 7-11 يوما فقد أظهرات زيادة زيادة أيضا في</p><p dir="RTL">االرتشاح من 75مليجرام/ m2&nbsp;25( مليجرام)kg/ وزيادة في التشوهات من 112.5 مليجرام m2/ 37.5( مليجرام )kg/ مشابهة لتلك</p><p dir="RTL">التشوهات التي تم رصدها بعد حقنها بجرعة واحدة &nbsp;داخل الصفاق. أما نتائج حقن الفئران بجرعة واحدة داخل الصضفاق من مشتق Bendamustine بنسبة 120 مليجرام m2/ 20( مليجرام/ )kg خالل أيام الحمل 4 و7و9و11 أو 13 فقد أظهرت هالك المضغة والموت الجنيني مصحوبة بزيادة في االرتشاح وانخفاض في عدد األجنة</p><p dir="RTL">الحية.</p><p dir="RTL">كماتم رصد زيادة في التشوهات الخارجية والداخلية في الفئران المحقونة&nbsp; بجرعات من الدواء . وشملت هذه التشوهات الخارجية {</p><p dir="RTL">الذيل , الرأس , حدوث انفتاق في األعضاء الخارجية (الفتق السري) } وتضمنت التشوهات الداخلية (تمويه الكلية واستسقاء الرأس.)</p><p dir="RTL">والتوجد أي دراسات مستفيضة ودقيقة بشكل جيد على النساء الحوامل حتى اآلن. إذا تم استخدام هذا الدواء خالل الحمل أو لو أصبحت المريضة حامال في ماالتزال تتناوله كعالج لها, فإنه من المختم ضرورة إبالغها</p><p dir="RTL">بالمخاطر المحتملة على جنينها.</p><p>&nbsp;</p><p dir="RTL">الرضاعة الطبيعية يجب عدم تناول ريبوماستين أثناء الرضاعة الطبيعية. إذا لزم العالج باستخدام ريبوماستين أثناء الرضاعة، فيجب إيقاف الرضاعة</p><p dir="RTL">الطبيعية.</p><p dir="RTL">اسأل الطبيب أو الصيدلي لالستشارة قبل تناول أي دواء.</p><p>&nbsp;</p><p>القيادة واستخدام اآلالت</p><p dir="RTL">لم يتم إجراء أية دراسات حول التأثيرات الناتجة على إمكانية القيادة واستخدام الماكينات.ال تقد سيارة أو تشغل ماكينة إذا عانيت من</p><p dir="RTL">آثار جانبية مثل الدوار أو عدم االتزان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أو بالتزامن مع أدوية</p><p dir="RTL">دقيقة على جرعات عديدة إما بمفردها (عالج أحادي)</p><p dir="RTL">يُعطى&nbsp;ريبوماستين في الوريد على مدار&nbsp;60-30</p><p dir="RTL">أخرى.</p><p dir="RTL">يجب عدم بدء العالج في حالة انخفاض عدد خاليا الدم البيضاء إلى ما دون 3.000&nbsp; خلية/ميكروليتر أو انخفاض عدد الصفيحات</p><p dir="RTL">الدموية إلى ما دون 75.000&nbsp; خلية/ميكروليتر.</p><p dir="RTL">سيحدد الطبيب هذه القيم على فترات زمنية منتظمة.</p><p>&nbsp;</p><p>ابيضاض الخاليا اللمفاوية المزمن</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">ريبوماستين 100 &nbsp;ملجم/متر مربع من مساحة سطح الجسم (وفقًا لطولك ووزنك)</p></td><td style="vertical-align:top"><p dir="RTL">في األيام 2+1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">ك&nbsp;ِّ&nbsp;رر الدورة بعد&nbsp;4&nbsp; أسابيع&nbsp;6&nbsp;&nbsp;مرات</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>هودجكن</strong></p><p dir="RTL"><strong>بخالف</strong></p><p dir="RTL"><strong>األخرى</strong></p><p dir="RTL"><strong>من األنواع</strong></p><p dir="RTL"><strong>الليمفاوية</strong></p><p dir="RTL"><strong>األورام</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">ريبوماستين 120 &nbsp;ملجم/متر مربع من مساحة سطح الجسم (وفقًا لطولك ووزنك)</p></td><td style="vertical-align:top"><p dir="RTL">في األيام 2+1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">ك&nbsp;ِّ&nbsp;رر الدورة بعد&nbsp;3&nbsp; أسابيع&nbsp;6&nbsp; مرات على األقل</p></td></tr></tbody></table><p><strong>&nbsp;&nbsp;</strong></p><p dir="RTL"><strong>ورم خاليا نخاع العظام الخبيث المتعدد</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">120<em> </em><em>&ndash;</em> &nbsp;&nbsp;150 &nbsp;ريبوماستين ملجم/متر مربع من مساحة سطح الجسم (وفقًا لطولك ووزنك)</p></td><td style="vertical-align:top"><p dir="RTL">في األيام 2+1</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بريدنيزون 60 ملجم/متر مربع من مساحة سطح الجسم (وفقًا لطولك ووزنك) بالحقن الوريدي أو عن طريق</p><p dir="RTL">الفم</p></td><td style="vertical-align:top"><p dir="RTL">في األيام 4-1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">ك&nbsp;ِّ&nbsp;رر الدورة بعد&nbsp;4&nbsp; أسابيع&nbsp;3&nbsp; مرات على األقل</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL">/75.000ميكروليتر، على</p><p>&nbsp;</p><p dir="RTL">/3.000ميكروليتر أو &lt;</p><p>&nbsp;</p><p dir="RTL">يجب إنهاء العالج عند انخفاض قيم كرات الدم البيضاء و/أو الصفيحات إلى &lt;</p><p>&nbsp;</p><p dir="RTL">/4.000ميكروليتر وقيم الصفيحات إلى &gt;</p><p>&nbsp;</p><p dir="RTL">التوالي. يمكن مواصلة العالج بعد زيادة قيم كرات الدم البيضاء إلى &gt;</p><p>.ميكروليتر/100.000</p><p>&nbsp;</p><p dir="RTL">في حالة الخلل المتوسط في وظائف الكبد.)ال يلزم تعديل</p><p>&nbsp;</p><p dir="RTL"><u>ق</u><u>صور</u><u> </u><u>و</u><u>ظا</u><u>ئ</u><u>ف</u><u> </u><u>ا</u><u>ل</u><u>ك</u><u>ب</u><u>د</u><u> أو الكلى</u></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1026" type="#_x0000_t75"
 style='position:absolute;margin-left:296.95pt;margin-top:3.85pt;width:5.75pt;
 height:10pt;z-index:1240;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="13" src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />وفقًا لدرجة قصور وظائف الكبد، قد يلزم تعديل الجرعة (بخفضها 30</p><p>&nbsp;</p><p dir="RTL">الجرعة في حالة قصور وظائف الكلى.سيقرر الطبيب ما إذا كان من الضروري تعديل الجرعة أم ال.</p><p dir="RTL"><u>ك</u><u>ي</u><u>ف</u><u>ي</u><u>ة</u><u> االستخدام</u> يجب أن يتولى فقط األطباء أصحاب الخبرة في عالج األورام العالج باستخدام ريبوماستين.سيعطيك طبيبك الجرعة المناسبة من دواء</p><p dir="RTL">ريبوماستين متب &nbsp;ًعا في ذلك االحتياطات الالزمة.</p><p dir="RTL">سيعطيك&nbsp;طبيبك المقيم محلول التسريب الوريدي بعد تحضيره وفق الوصفة الطبية.&nbsp;يُعطى&nbsp;المحلول في الوريد عن طريق التسريب</p><p dir="RTL">الوريدي قصير األجل لمدة 60-30 &nbsp;دقيقة.</p><p>&nbsp;</p><p dir="RTL"><u>فترة</u><u> االستخدام</u></p><p dir="RTL">ال يوجد حد زمني موضوع كقاعدة عامة للعالج باستخدام ريبوماستين. تتوقف فترة االستخدام على المرض واالستجابة للعالج.</p><p>&nbsp;</p><p dir="RTL">إذا كنت قلقًا أو كانت لديك أية استفسارات حول العالج باستخدام ريبوماستين، فيرجى التحدث إلى الطبيب أو الممرضة.</p><p>&nbsp;</p><p>في حالة نسيان استخدام ريبوماستين</p><p dir="RTL">في حالة نسيان أخذ جرعة من دواء ريبوماستين، سيلتزم طبيبك عادة بجدول الجرعات العادية.</p><p>&nbsp;</p><p>في حالة إيقاف استخدام ريبوماستين</p><p dir="RTL">سيقرر الطبيب المعالج ما إذا كان سيقطع العالج أو سيتحول إلى مستحضر دوائي آخر.</p><p dir="RTL">إذا كانت لديك أية استفسارات أخرى حول استخدام هذا المنتج، فاسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong>كما هو الحال مع جميع األدوية، من الممكن أن يتسبب ريبوماستين في ظهور آثار جانبية ولكنها ال تحدث لجميع المرضى.</p><p dir="RTL">يتم استخدام تعريفات التكرار التالية عند تقييم اآلثار الجانبية:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">آثار شائعة جدًا</p></td><td style="vertical-align:top"><p dir="RTL">تظهر في أكثر من مريض من كل 10&nbsp; مرضى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">آثار شائعة</p></td><td style="vertical-align:top"><p dir="RTL">تظهر في مريض حتى 10 &nbsp;مرضى من كل 100 &nbsp;مريض</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">آثار غير شائعة</p></td><td style="vertical-align:top"><p dir="RTL">تظهر في مريض حتى 10 &nbsp;مرضى من كل 1000 &nbsp;مريض</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">آثار نادرة</p></td><td style="vertical-align:top"><p dir="RTL">تظهر في مريض حتى 10 &nbsp;مرضى من كل 10000 &nbsp;مريض</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">آثار نادرة جدًا</p></td><td style="vertical-align:top"><p dir="RTL">تظهر في أقل من مريض من كل 10000&nbsp; مرضى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">آثار غير معروفة</p></td><td style="vertical-align:top"><p dir="RTL">ال يمكن تقدير مرات التكرار من البيانات المتاحة</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">لوحظت حدوث تغيرات في األنسجة (نخر)بشكل نادر جدًا بعد الحقن عن طريق الخطأ في النسيج خارج األوعية الدموية. قد يشير الشعور بحرقة شديدة في موضع إدخال إبرة التسريب الوريدي إلى أن الدواء تم إعطاؤه خارج األوعية الدموية.قد تكون نتائج إعطاء</p><p dir="RTL">الدواء بهذه الطريقة أل ًما وتشوهات جلدية يصعب التئامها.</p><p dir="RTL">التأثير الجانبي المقتصر على جرعة ريبوماستين هو قصور وظيفة النخاع العظمي التي تعود في العادة إلى طبيعتها بعد العالج.</p><p dir="RTL">يؤدي تثبيط وظيفة النخاع العظمي إلى زيادة خطورة العدوى.</p><p>&nbsp;</p><p>آثار شائعة ج ًدا:</p><p dir="RTL"><em>&bull;</em> انخفاض عدد كرات الدم البيضاء</p><p dir="RTL"><em>&bull;</em> انخفاض الصبغة الحمراء للدم (الهيموجلوبين)</p><p dir="RTL"><em>&bull;</em> انخفاض عدد الصفيحات</p><p dir="RTL"><em>&bull;</em> حاالت العدوى</p><p dir="RTL"><em>&bull;</em> الغثيان<em> </em><em>&bull;</em> القيء<em> &bull;</em> التهاب مخاطي</p><p dir="RTL"><em>&bull;</em> زيادة مستوى الكرياتينين في الدم</p><p dir="RTL"><em>&bull;</em> زيادة مستوى البولينا في الدم</p><p dir="RTL"><em>&bull;</em> حمى<em> </em><em>&bull;</em> اإلجهاد</p><p><em>&nbsp;</em></p><p>آثار شائعة:</p><p dir="RTL"><em>&bull;</em> نزيف<em> &bull;</em> اضطراب التمثيل الغذائي الناتج عن خاليا السرطان الميتة التي تفرز محتوياتها في مجرى الدم</p><p dir="RTL"><em>&bull;</em> االنخفاض في خاليا الدم الحمراء الذي يمكن أن يتسبب في شحوب الجلد أو الضعف أو صعوبة التنفس (فقر الدم)</p><p dir="RTL"><em>&bull;</em> انخفاض عدد العدالت</p><p>&nbsp;</p><p dir="RTL">والشرى</p><p>&nbsp;</p><p dir="RTL"><em>&bull;</em> تفاعالت فرط الحساسية مثل التهاب الجلد التحسسي (التهاب الجلد)</p><p dir="RTL"><em>&bull;</em> زيادة إنزيمات الكبد ناقلة األمين األسبارتي/ناقلة األمين األالنينية</p><p dir="RTL"><em>&bull;</em> زيادة إنزيم الفوسفاتيز القلوي</p><p dir="RTL"><em>&bull;</em> زيادة الصبغة الصفراوية</p><p dir="RTL"><em>&bull;</em> انخفاض مستويات البوتاسيوم في الدم</p><p dir="RTL"><em>&bull;</em> اختالل وظيفة القلب<em> &bull;</em> عدم انتظام ضربات القلب<em> &bull;</em> زيادة الضغط أو انخفاضه</p><p>&nbsp;</p><p dir="RTL"><em>&bull;</em> &nbsp;خلل وظائف الرئة</p><p dir="RTL"><em>&bull;</em> اإلسهال</p><p dir="RTL"><em>&bull;</em> اإلمساك</p><p dir="RTL"><em>&bull;</em> التهاب الفم</p><p dir="RTL"><em>&bull;</em> فقدان الشهية</p><p dir="RTL"><em>&bull;</em> &nbsp;فقدان الشعر</p><p dir="RTL"><em>&bull;</em> تغيرات جلدية</p><p dir="RTL"><em>&bull;</em> &nbsp;انقطاع الطمث</p><p dir="RTL"><em>&bull;</em> ألم</p><p>&nbsp;</p><p dir="RTL"><em>&bull;</em> األرق<em> </em><em>&bull;</em> القشعريرة<em> </em><em>&bull;</em> الجفاف</p><p><em>&nbsp;</em></p><p>آثار غير شائعة:</p><p dir="RTL"><em>&bull;</em> تراكم السائل في كيس القلب (هروب السائل إلى الفراغ التاموري)</p><p><em>&nbsp;</em></p><p>آثار نادرة الحدوث:</p><p dir="RTL"><em>&bull;</em> عدوى الدم (اإلنتان)</p><p dir="RTL"><em>&bull;</em> تفاعالت فرط الحساسية الحادة (تفاعالت تأقية)</p><p dir="RTL"><em>&bull;</em> عالمات شبيهة بالتفاعالت التأقية (تفاعالت تأقانية)</p><p dir="RTL"><em>&bull;</em> النعاس</p><p dir="RTL"><em>&bull;</em> فقدان الصوت</p><p dir="RTL"><em>&bull;</em> هبوط حاد في الدورة الدموية</p><p dir="RTL"><em>&bull;</em> احمرار الجلد</p><p dir="RTL"><em>&bull;</em> التهاب الجلد</p><p dir="RTL"><em>&bull;</em> الحكة الجلدية</p><p dir="RTL"><em>&bull;</em> &nbsp;الطفح الجلدي</p><p dir="RTL"><em>&bull;</em> زيادة التعرق</p><p><em>&nbsp;</em></p><p>آثار نادرة ج ًدا:</p><p dir="RTL"><em>&bull;</em> التهاب الرئتين األولي غير النمطي<em>)</em>االلتهاب الرئوي)</p><p dir="RTL"><em>&bull;</em> انهيار خاليا الدم الحمراء</p><p dir="RTL"><em>&bull;</em>&nbsp;انخفاض&nbsp;سريع في ضغط الدم مصحو&nbsp;ًبا&nbsp;أحيانًا&nbsp;بتفاعالت&nbsp;جلدية أو تقيح&nbsp;(صدمة&nbsp;تأقية)</p><p dir="RTL"><em>&bull;</em> اختالل حاسة التذوق</p><p dir="RTL"><em>&bull;</em> تنميل</p><p dir="RTL"><em>&bull;</em> توعك وألم في األطراف (اعتالل األعصاب الطرفية)</p><p dir="RTL"><em>&bull;</em> مرض الجهاز العصبي (المتالزمة المضادة إلفراز األسيتيل كولين)</p><p dir="RTL"><em>&bull;</em> اضطرابات األعصاب</p><p dir="RTL"><em>&bull;</em> نقص االتزان (خلل الحركة)</p><p dir="RTL"><em>&bull;</em> &nbsp;التهاب المخ</p><p dir="RTL"><em>&bull;</em> زيادة معدل ضربات القلب</p><p dir="RTL"><em>&bull;</em> نوبة قلبية، وألم الصدر (احتشاء عضلة القلب)</p><p dir="RTL"><em>&bull;</em> فشل القلب</p><p dir="RTL"><em>&bull;</em> &nbsp;التهاب األوردة</p><p dir="RTL"><em>&bull;</em> تليف الرئة</p><p dir="RTL"><em>&bull;</em> &nbsp;التهاب المريء المصحوب بنزيف</p><p dir="RTL"><em>&bull;</em> نزيف المعدة أو األمعاء</p><p dir="RTL"><em>&bull;</em> عقم</p><p dir="RTL"><em>&bull;</em> فشل عضوي متعدد</p><p dir="RTL">تم اإلبالغ عن أورام ثانوية (متالزمة خلل التنسج النخاعي، سرطان الدم النخاعي الحاد، سرطان الشعب الهوائية) &nbsp;بعد العالج</p><p dir="RTL">باستخدام ريبوماستين. تعذر تحديد وجود صلة واضحة بين هذه األورام ودواء ريبوماستين .</p><p dir="RTL">المتموتة السمي.)</p><p dir="RTL">البشرة</p><p dir="RTL">أنسجة</p><p dir="RTL">وتقشر</p><p dir="RTL">جونسون</p><p dir="RTL">ستيفين</p><p dir="RTL">تم اإلبالغ عن عدد صغير من حاالت تفاعالت الجلد الحادة (متالزمة</p><p dir="RTL">إال أن صلتها بدواء ريبوماستين غير واضحة.</p><p dir="RTL">إذا&nbsp;بلغ&nbsp;أي من اآلثار الجانبية حد الخطورة أو إذا الحظت أي آثار جانبية غير موضحة في هذه النشرة، فيُرجى&nbsp;إخطار الطبيب.</p><p dir="RTL">لإلبالغ عن األعراض الجانبية: المركز الوطني للتيقظ والسالمة الدوائية فاكس : 00966112057662</p><p dir="RTL">لالتصال بالإلدارة التنفيذية للتيقظ وإدارة األزمات.</p><p>+966-11-2038222 : هاتف 2356,2334,2317,2340,2354,2353 :تحوبلة</p><p>8002490000 :المجاني الهاتف npc.drug@sfda.gov.sa :إلكتروني البريد www.sfda.gov.sa/npc:االلكتروني الموقع</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong>يحفظ بعيدًا عن متناول األطفال ونطاق رؤيتهم. ال تستخدم الدواء بعد انتهاء تاريخ الصالحية المذكور على الملصق والعبوة. ويشير تاريخ انتهاء الصالحية إلى آخر يوم في ذلك</p><p dir="RTL">الشهر.</p><p dir="RTL">احفظ الحاوية في العبوة الخارجية لحماية المحتويات من الضوء.</p><p dir="RTL">يُخزن في درجة حرارة أقل من 30 درجة مئوية.</p><p>مالحظة بشأن فترة الصالحية بعد فتح المحلول أو تحضيره</p><p dir="RTL">تظل محاليل التسريب الوريدي التي يتم تحضيرها وفقًا للتعليمات الواردة في نهاية هذه النشرة ثابتة في أكياس البولي إيثيلين في درجة</p><p dir="RTL">حرارة الغرفة&nbsp;25&nbsp;درجة&nbsp;مئوية&nbsp;ورطوبة نسبية بمقدار&nbsp;<!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:5.5pt;height:10pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="7" height="13" src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />60&nbsp;&nbsp;لمدة ثالث ساعات ونصف وفي الثالجة تظل ثابتة لمدة يومين.ال&nbsp;يحتوي</p><p dir="RTL">دواء ريبوماستين على مواد حافظة. لذا يجب عدم استخدام المحاليل بعد هذه الفترات.</p><p dir="RTL">يتحمل المستخدم مسئولية الحفاظ على ظروف التعقيم. ال يجب التخلص من األدوية بإلقائها في مياه الصرف أو المخلفات المنزلية. ولكن اسأل الصيدلي عن كيفية التخلص من األدوية التي لم</p><p dir="RTL">تعد هناك حاجة إليها. فسوف تساعد هذه اإلجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي هيدروكلوريد بينداموستين.</p><p dir="RTL">ملجم من هيدروكلوريد بينداموستين ملجم من هيدروكلوريد بينداموستين</p><p dir="RTL">قارورة تحتوي على 25</p><p dir="RTL">قارورة تحتوي على 100</p><p dir="RTL">بعد اإلذابة، يحتوي الملي لتر من المركز على 2.5&nbsp; ملجم هيدروكلوريد بينداموستين.</p><p>المكون اآلخر هو مانيتول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قارورة زجاجية بنية اللون مزودة بسدادة مطاطية وغطاء ألومونيوم قابل للنزع.</p><p dir="RTL">المسحوق أبيض بللوري.</p><p dir="RTL">ريبوماستين متوفر في عبوات تحتوي على</p><p dir="RTL">ملجم من هيدروكلوريد بينداموستين</p><p dir="RTL">قارورة حقن بها 25</p><p>20 ،10 ،5</p><p dir="RTL">و</p><p dir="RTL">ملجم من هيدروكلوريد بينداموستين.</p><p>100</p><p dir="RTL">قوارير حقن بها</p><p>5و1</p><p dir="RTL">قد ال تتوفر جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p><strong>مالك&nbsp;التفويض&nbsp;بالتسويق</strong></p><p>Astellas Pharma GmbH Postfach 50 01 66 D-80971 M&uuml;nchen</p><p>Germany</p><p><strong>جهة التصنيع</strong></p><p>Oncotec Pharma Produktion GmbH</p><p>Am Pharmapark 06861 Dessau-Ro&szlig;lau</p><p>Germany</p><p dir="RTL">( لكل دول الخليج)</p><p>or Cenexi-Laboratoires Thissen SA</p><p>Rue de la Papyr&eacute;e 2 6 B-1420 Braine-L&rsquo;Alleud</p><p>Belgium</p><p dir="RTL">( لكل دول الخليج ما عدا االمارات و عمان)</p><p><strong>الصانع مسؤوال عن إطالق دفعة</strong></p><p>Haupt Pharma Wolfratshausen GmbH,</p><p>Pfaffenrieder Stra&szlig;e 5,</p><p>82515 Wolfratshausen, Germany</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر اعتماد لهذه النشرة في: في نوفمبر (تشرين الثاني) 2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ribomustin™ 25 mg, powder for concentrate for solution for infusion Ribomustin™ 100 mg, powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 25 mg bendamustine hydrochloride. One vial contains 100 mg bendamustine hydrochloride.
1 ml of the concentrate contains 2.5 mg bendamustine hydrochloride when reconstituted according to section 6.6.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion White, microcrystalline powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.</p><p>&nbsp;</p><p>Indolent non-Hodgkin&rsquo;s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.</p><p>&nbsp;</p><p>Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For intravenous infusion over 30 - 60 minutes (see section 6.6).</p><p>Infusion must be administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.</p><p>&nbsp;</p><p>Poor bone marrow function is related to increased chemotherapy-induced haematological toxicity. Treatment should not be started if leukocyte and/or platelet values dropped to &lt; 3,000/&micro;l or &lt; 75,000/&micro;l, respectively (see section 4.3).</p><p>&nbsp;</p><p>Monotherapy for chronic lymphocytic leukaemia</p><p>100 mg/m&sup2; body surface area bendamustine hydrochloride on days 1 and 2; every 4 weeks.</p><p>&nbsp;</p><p>Monotherapy for indolent non-Hodgkin&rsquo;s lymphomas refractory to rituximab</p><p>120 mg/m&sup2; body surface area bendamustine hydrochloride on days 1 and 2; every 3 weeks.</p><p>&nbsp;</p><p>Multiple myeloma</p><p>120 - 150 mg/m&sup2; body surface area bendamustine hydrochloride on days 1 and 2, 60 mg/m&sup2; body surface area prednisone i.v. or per os on days 1 to 4; every 4 weeks.</p><p>&nbsp;</p><p>&nbsp;</p><p>Treatment should be terminated or delayed if leukocyte and/or platelet values dropped to &lt; 3,000/&micro;l or &lt; 75,000/&micro;l, respectively. Treatment can be continued after leukocyte values have increased to &gt; 4,000/&micro;l and platelet values to &gt; 100,000/&micro;l.</p><p>&nbsp;</p><p>The leukocyte and platelet Nadir is reached after 14-20 days with regeneration after 3-5 weeks. During therapy free intervals strict monitoring of the blood count is recommended (see section 4.4).</p><p>&nbsp;</p><p>In case of non-haematological toxicity dose reductions have to be based on the worst CTC grades in the preceding cycle. A 50% dose reduction is recommended in case of CTC grade 3 toxicity. An interruption of treatment is recommended in case of CTC grade 4 toxicity.</p><p>If a patient requires a dose modification the individually calculated reduced dose must be given on day 1 and 2 of the respective treatment cycle.</p><p>For preparation and administration instructions see section 6.6. Hepatic impairment</p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with mild hepatic impairment (serum bilirubin &lt; 1.2mg/dl). A 30% dose reduction is recommended in patients with moderate hepatic impairment (serum bilirubin 1.2 - 3.0 mg/dl).</p><p>No data is available in patients with severe hepatic impairment (serum bilirubin values of &gt; 3.0 mg/dl) (see section 4.3).</p><p>&nbsp;</p><p>Renal impairment</p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with a creatinine clearance of &gt; 10 ml/min. Experience in patients with severe renal impairment is limited.</p><p>&nbsp;</p><p>Paediatric patients</p><p>There is no experience in children and adolescents with Ribomustin.</p><p>&nbsp;</p><p>Elderly patients</p><p>There is no evidence that dose adjustments are necessary in elderly patients (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients (see section 6.1) During breast-feeding
Severe hepatic impairment (serum bilirubin > 3.0 mg/dl) Jaundice
Severe bone marrow suppression and severe blood count alterations (leukocyte and/or platelet values dropped to < 3,000/µl or < 75,000/µl, respectively)
Major surgery less than 30 days before start of treatment Infections, especially involving leukocytopenia
Yellow fever vaccination

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Myelosuppression</p><p>Patients treated with bendamustine hydrochloride may experience myelosuppression. In the event of treatment-related myelosuppression, leukocytes, platelets, haemoglobin, and neutrophils must be monitored at least weekly. Prior to the initiation of the next cycle of therapy, the following parameters are recommended: Leukocyte and/or platelet values &gt; 4,000/&micro;l or &gt; 100,000/&micro;l, respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>Infections</p><p>Infection, including pneumonia and sepsis, has been reported. In rare cases, infection has been associated with hospitalization, septic shock and death. Patients with neutropenia and/or lymphopenia following</p><p>&nbsp;</p><p>&nbsp;</p><p>treatment with bendamustine hydrochloride are more susceptible to infections. Patients with myelosuppression following bendamustine hydrochloride treatment should be advised to contact a physician if they have symptoms or signs of infection, including fever or respiratory symptoms.</p><p>&nbsp;</p><p>Skin reactions</p><p>A number of skin reactions have been reported. These events have included rash, toxic skin reactions and bullous exanthema. Some events occurred when bendamustine hydrochloride was given in combination with other anticancer agents, so the precise relationship is uncertain. Where skin reactions occur, they may be progressive and increase in severity with further treatment. If skin reactions are progressive, Ribomustin should be withheld or discontinued. For severe skin reactions where a relationship to bendamustine hydrochloride is suspected, treatment should be discontinued.</p><p>&nbsp;</p><p>Patients with cardiac disorders</p><p>During treatment with bendamustine hydrochloride the concentration of potassium in the blood must be closely monitored and potassium supplement must be given when K+ &lt;3,5 mEq/l, and ECG measurement must be performed.</p><p>&nbsp;</p><p>Nausea, vomiting</p><p>An antiemetic may be given for the symptomatic treatment of nausea and vomiting.</p><p>&nbsp;</p><p>Tumour lysis syndrome</p><p>Tumour lysis syndrome associated with Ribomustin treatment has been reported in patients in clinical trials. The onset tends to be within 48 hours of the first dose of Ribomustin and, without intervention, may lead to acute renal failure and death. Preventive measures include adequate volume status, close monitoring of blood chemistry, particularly potassium and uric acid levels. The use of allopurinol during the first one to two weeks of Ribomustin therapy can be considered but not necessarily as standard.</p><p>However, there have been a few cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis reported when bendamustine and allopurinol are administered concomitantly.</p><p>&nbsp;</p><p>Anaphylaxis</p><p>Infusion reactions to bendamustine hydrochloride have occurred commonly in clinical trials. Symptoms are generally mild and include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred. Patients must be asked about symptoms suggestive of infusion reactions after their first cycle of therapy. Measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids must be considered in subsequent cycles in patients who have previously experienced infusion reactions.</p><p>Patients who experienced Grade 3 or worse allergic-type reactions were typically not re-challenged.</p><p>Contraception</p><p>Bendamustine hydrochloride is teratogenic and mutagenic.</p><p>Women should not become pregnant during treatment. Male patients should not father a child during and up to 6 months after treatment. They should seek advice about sperm conservation prior to treatment with bendamustine hydrochloride because of possible irreversible infertility.</p><p>Extravasation</p><p>An extravasal injection should be stopped immediately. The needle should be removed after a short aspiration. Thereafter the affected area of tissue should be cooled. The arm should be elevated. Additional treatments like the use of corticosteroids are not of clear benefit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No <em>in-vivo </em>interaction studies have been performed.</p><p>&nbsp;</p><p>&nbsp;</p><p>When Ribomustin is combined with myelosuppressive agents, the effect of Ribomustin and/or the</p><p>co-administered medicinal products on the bone marrow may be potentiated. Any treatment reducing the patient&rsquo;s performance status or impairing bone marrow function can increase the toxicity of Ribomustin.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Combination of Ribomustin with cyclosporine or tacrolimus may result in excessive immunosuppression with risk of lymphoproliferation.</p><p>&nbsp;</p><p>Cytostatics can reduce antibody formation following live-virus vaccination and increase the risk of infection which may lead to fatal outcome. This risk is increased in subjects who are already immunosuppressed by their underlying disease.</p><p>&nbsp;</p><p>Bendamustine metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme (see section 5.2). Therefore, potential for interaction with CYP1A2 inhibitors such as fluvoxamine, ciprofloxacin, acyclovir, cimetidine exists.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Ribomustin can cause fetal harm when administered to a pregnant woman. Single intraperitoneal doses of bendamustine from 210 mg/m2 (70 mg/kg) in mice administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (exencephaly, cleft palates, accessory rib, and spinal deformities) and decreased fetal body weights. This dose did not appear to be maternally toxic and lower doses were not evaluated. Repeat intraperitoneal dosing in mice on gestation days 7-11 resulted in an increase in resorptions from 75 mg/m2 (25 mg/kg) and an increase in abnormalities from 112.5 mg/m2 (37.5 mg/kg) similar to those seen after a single intraperitoneal administration. Single intraperitoneal&nbsp; doses of bendamustine from 120 mg/m2 (20 mg/kg) in rats administered on gestation days 4, 7, 9, 11, or 13 caused embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses.&nbsp; A significant increase in external [effect on tail, head, and herniation of external organs (exomphalos)]&nbsp; and internal (hydronephrosis and hydrocephalus) malformations were seen in dosed rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p><p>&nbsp;</p><p>Breast-feeding</p><p>It is not known whether bendamustine passes into the breast milk, therefore, Ribomustin is contraindicated during breast-feeding (see section 4.3). Breast-feeding must be discontinued during treatment with Ribomustin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, ataxia, peripheral neuropathy and somnolence have been reported during treatment with Ribomustin (see section 4.8). Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving and using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions with bendamustine hydrochloride are hematological adverse reactions (leukopenia, thrombopenia), dermatologic toxicities (allergic reactions), constitutional symptoms (fever), gastrointestinal symptoms (nausea, vomiting).</p><p>The table below reflects the data obtained with bendamustine hydrochloride in clinical trials.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:line id="_x0000_s1026"
 style='position:absolute;z-index:-30592;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' from="239.7pt,244.95pt" to="243.05pt,244.95pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--><img width="6" height="1" src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system</strong></p><p><strong>organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common &ge;1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge;1/100 to &lt;1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge;1/1,000 to</strong></p><p><strong>&lt;1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge;1/10,000 to &lt;1/1,</strong></p><p><strong>000</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p><strong>&lt;1/10, 000</strong></p></td><td style="vertical-align:top"><p><strong><u>Not known</u></strong></p><p><strong><u>(cannot be</u></strong></p><p><strong><u>estimated</u></strong></p><p><strong><u>from the</u></strong></p><p><strong><u>available</u></strong></p><p><strong><u>data)</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Infection NOS*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sepsis</p></td><td style="vertical-align:top"><p>Pneumonia primary atypical</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasma benign, malignant</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tumour lysis syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Leukopenia NOS*, Thrombocytopenia</p></td><td style="vertical-align:top"><p>Haemorrhage, Anaemia, Neutropenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p><p>NOS*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic</p><p>reaction,</p><p>Anaphylactoid</p><p>reaction</p></td><td style="vertical-align:top"><p>Anaphylactic</p><p>shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Somnolence,</p><p>Aphonia</p></td><td style="vertical-align:top"><p>Dysgeusia,</p><p>Paraesthesia,</p><p>Peripheral</p><p>sensory</p><p>neuropathy,</p><p>Anticholiner</p><p>gic</p><p>syndrome,</p><p>Neurological</p><p>disorders,</p><p>Ataxia,</p><p>Encephalitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac</p><p>dysfunction,</p><p>such as</p><p>palpitations,</p><p>angina pectoris,</p><p>Arrhythmia</p></td><td style="vertical-align:top"><p>Pericardial</p><p>effusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia,</p><p>Myocardial</p><p>infarction,</p><p>Cardiac</p><p>failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension, hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute circulatory failure</p></td><td style="vertical-align:top"><p>Phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p><p>thoracic and</p><p>media-stinal</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary</p><p>dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary</p><p>fibrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>disorders</p></td><td style="vertical-align:top"><p>Nausea, Vomiting</p></td><td style="vertical-align:top"><p>Diarrhoea,</p><p>Constipation,</p><p>Stomatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>haemorrhagi</p><p>c</p><p>oesophagitis,</p><p>Gastrointesti</p><p>nal</p><p>haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia,</p><p>Skin disorders NOS*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema,</p><p>Dermatitis, Pruritus, makular-papular rash, Hyperhidrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amenorrhea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infertility</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders</p></td><td style="vertical-align:top"><p>Mucosal</p></td><td style="vertical-align:top"><p>Pain, Chills,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Multi organ</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>and administration site conditions</p></td><td style="vertical-align:top"><p>inflammation, Fatigue, Pyrexia</p></td><td style="vertical-align:top"><p>Dehydration, Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Haemoglobin decrease, Creatinine increase, Urea increase</p></td><td style="vertical-align:top"><p>AST increase, ALT increase, Alkaline phosphatase increase, Bilirubin increase, Hypokalemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>NOS = Not otherwise specified</p><p>&nbsp;</p><p>A small number of cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis have been reported in patients using bendamustine in combination with allopurinol or in combination with allopurinol and rituximab.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:line id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;z-index:-30568;
 mso-position-horizontal-relative:page' from="378.55pt,24.45pt" to="381.3pt,24.45pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="5" height="1" src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />The CD4/CD8 ratio may be reduced. A reduction of the lymphocyte count was seen. In immuno- suppressed patients, the risk of infection (e.g. with herpes zoster) may be increased.</p><p>&nbsp;</p><p>There have been isolated reports of necrosis after accidental extra-vascular administration and toxic epidermal necrosis, tumour lysis syndrome, and anaphylaxis.</p><p>&nbsp;</p><p>There are reports of secondary tumours, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukaemia and bronchial carcinoma. The association with Ribomustin therapy has not been determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After application of a 30 min infusion of Ribomustin once every 3 weeks the maximum tolerated dose (MTD) was 280 mg/m&sup2;. Cardiac events of CTC grade 2 which were compatible with ischaemic ECG changes occurred which were regarded as dose limiting.</p><p>In a subsequent study with a 30 min infusion of Ribomustin at day 1 and 2 every 3 weeks the MTD was found to be 180 mg/m2. The dose limiting toxicity was grade 4 thrombocytopenia. Cardiac toxicity was not dose limiting with this schedule.</p><p>&nbsp;</p><p>Counter measures</p><p>There is no specific antidote. Bone marrow transplantation and transfusions (platelets, concentrated erythrocytes) may be made or haematological growth factors may be given as effective countermeasures to control haematological side-effects.</p><p>Bendamustine hydrochloride and its metabolites are dialyzable to a small extent.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, ATC code:</p><p>&nbsp;</p><p>Bendamustine hydrochloride is an alkylating antitumour agent with unique activity. The antineoplastic and cytocidal effect of bendamustine hydrochloride is based essentially on a cross-linking of DNA single</p><p>&nbsp;</p><p>&nbsp;</p><p>and double strands by alkylation. As a result, DNA matrix functions and DNA synthesis and repair are impaired. The antitumour effect of bendamustine hydrochloride has been demonstrated by several in-vitro studies in different human tumour cell lines (breast cancer, non-small cell and small cell lung cancer, ovary carcinoma and different leukaemia) and in-vivo in different experimental tumour models with tumours of mouse, rat and human origin (melanoma, breast cancer, sarcoma, lymphoma, leukaemia and small cell lung cancer).</p><p>Bendamustine hydrochloride showed an activity profile in human tumour cell lines different to that of other alkylating agents. The active substance revealed no or very low cross-resistance in human tumour cell lines with different resistance mechanisms at least in part due to a comparatively persistent DNA interaction. Additionally, it was shown in clinical studies that there is no complete cross-resistance of bendamustine with anthracyclines, alkylating agents or rituximab. However, the number of assessed patients is small.</p><p>&nbsp;</p><p>Chronic lymphocytic leukaemia</p><p>The indication for use in chronic lymphocytic leukaemia is supported by a single open label study comparing bendamustine with chlorambucil. In <s>a </s>the prospective, multi-centre, randomised, study, 319 previously untreated patients with chronic lymphocytic leukaemia stage Binet B or C requiring therapy were included. The first line therapy with bendamustine hydrochloride 100 mg/m&sup2; i.v. on days 1 and 2 (BEN) was compared to treatment with chlorambucil 0.8mg/kg days 1 and 15 (CLB) for 6 cycles in both arms. Patients received allopurinol in order to prevent tumour lysis syndrome.</p><p>Patients with BEN have a significantly longer median progression free survival than patients with CLB treatment (21.5 versus 8.3 months, p &lt; 0.0001 in the latest follow-up). Overall survival was not statistically significantly different (median not reached). The median duration of remission is 19 months with BEN and 6 months with CLB treatment (p &lt; 0.0001). The safety evaluation in both treatment arms did not reveal any unexpected undesirable effects in nature and frequency. The dose of BEN was reduced in 34% of the patients. Treatment with BEN was discontinued in 3.9% of patients due to allergic reactions.</p><p>&nbsp;</p><p>Indolent non-Hodgkin&rsquo;s lymphomas</p><p>The indication for indolent non-Hodgkin&rsquo;s lymphomas relied on two uncontrolled phase II trials.</p><p><!--[if gte vml 1]><v:line
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;z-index:-30544;
 mso-position-horizontal-relative:page' from="129.75pt,11.7pt" to="132.5pt,11.7pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="5" height="1" src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />In the pivotal prospective, multi-centre, open study 100 patients with indolent B-cell non-Hodgkin&acute;s lymphomas refractory to rituximab mono- or combination therapy were treated with BEN single agent. Patients received a median of 3 previous chemotherapy or biologic therapy courses. The median number of previous rituximab-containing courses was 2. The patients had no response or progress within 6 months after rituximab treatment. The dose of BEN was 120 mg/m&sup2; i.v. on days 1 and 2 planned for at least 6 cycles. Duration of treatment depended on response (6 cycles planned). The overall response rate was 75% including 17% complete (CR and CRu) and 58% partial response as assessed by independent review committee. The median duration of remission was 40 weeks. BEN was generally well tolerated when given in this dose and schedule.</p><p>&nbsp;</p><p>The indication is further supported by another prospective, multi-centre, open study including 77 patients. The patient population was more heterogeneous including: indolent or transformed B-cell non-Hodgkin&rsquo;s lymphomas refractory to rituximab mono- or combination therapy. The patients had no response or progress within 6 months or had an untoward reaction to prior rituximab treatment. Patients received a median of 3 previous chemotherapy or biological therapy courses. The median number of previous rituximab-containing courses was 2. The overall response rate was 76% with a median duration of response of 5 months (29 [95% CI 22.1, 43.1] weeks).</p><p>&nbsp;</p><p>Multiple myeloma</p><p>In a prospective, multi-centre, randomised, open study 131 patients with advanced multiple myeloma (Durie-Salmon stage II with progress or stage III) were included. The first line therapy with bendamustine hydrochloride in combination with prednisone (BP) was compared to treatment with melphalan and prednisone (MP). Neither transplant-eligibility nor the presence of specific co-morbidities played <s>no </s>a role for inclusion into the trial. The dose was bendamustine hydrochloride 150 mg/m&sup2; i.v. on days 1 and 2 or melphalan 15 mg/m&sup2; i.v. on day 1 each in combination with prednisone. Duration of treatment depended on response and averaged 6.8 in the BP and 8.7 cycles in the MP group.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients with BP treatment have a longer median progression free survival than patients with MP (15 [95%Cl 12-21] versus 12 [95%Cl 10-14] months) (p=0.0566). The median time to treatment failure is 14 months with BP and 9 months with MP treatment. The duration of remission is 18 months with BP and 12 months with MP treatment. The difference in overall survival is not significantly different (35 months BP versus 33 months MP). Tolerability in both treatment arms was in line with the know safety profile of the respective medicinal products with significantly more dose reductions in the BP arm.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distribution</p><p>The elimination half-life t1/2&szlig; after 30 min i.v. infusion of 120 mg/m2 area to 12 subjects was 28.2 minutes.</p><p><!--[if gte vml 1]><v:line
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;z-index:-30520;
 mso-position-horizontal-relative:page' from="431.95pt,24.45pt" to="434.95pt,24.45pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="5" height="1" src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Following 30 min i.v. infusion the central volume of distribution was 19.3 l. Under steady-state conditions following i.v. bolus injection the volume of distribution was 15.8-20.5 l<s>L</s>.</p><p>More than 95% of the substance is bound to plasma proteins (primarily albumin).</p><p>&nbsp;</p><p>Metabolism</p><p>A major route of clearance of bendamustine is the hydrolysis to monohydroxy- and dihydroxy- bendamustine. Formation of N-desmethyl-bendamustine and gamma-hydroxy-bendamustine by hepatic metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme. Another major route of bendamustine metabolism involves conjugation with glutathione.</p><p>In-vitro bendamustine does not inhibit CYP 1A4, CYP 2C9/10, CYP 2D6, CYP 2E1 and CYP 3A4.</p><p>&nbsp;</p><p>Elimination</p><p>The mean total clearance after 30 min i.v. infusion of 120 mg/m2 body surface area to 12 subjects was</p><p>639.4 ml/minute. About 20% of the administered dose was recovered in urine within 24 hours. Amounts excreted in urine were in the order monohydroxy-bendamustine &gt; bendamustine &gt; dihydroxy- bendamustine &gt; oxidised metabolite &gt; N-desmethyl bendamustine. In the bile, primarily polar metabolites are eliminated.</p><p>&nbsp;</p><p>Hepatic impairment</p><p>In patients with 30 - 70% tumour infestation of the liver and mild hepatic impairment (serum bilirubin</p><p>&lt; 1.2 mg/dl) the pharmacokinetic behaviour was not changed. There was no significant difference to patients with normal liver and kidney function with respect to Cmax, tmax, AUC, t1/2&szlig; , volume of distribution and clearance. AUC and total body clearance of bendamustine correlate inversely with serum bilirubin.</p><p>&nbsp;</p><p>Renal impairment</p><p><!--[if gte vml 1]><v:line id="_x0000_s1027"
 style='position:absolute;left:0;text-align:left;z-index:-30496;
 mso-position-horizontal-relative:page' from="260.95pt,11.75pt" to="264.05pt,11.75pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="5" height="1" src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />In patients with creatinine clearance &gt;10 ml/min including dialysis dependent patients, no significant difference to patients with normal liver and kidney function was observed with respect to Cmax, tmax, AUC, t1/2&szlig;, volume of distribution and clearance.</p><p>&nbsp;</p><p>Elderly subjects</p><p>Subjects up to 84 years of age were included in pharmacokinetic studies. Higher age does not influence the pharmacokinetics of bendamustine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:</p><p>Histological investigations in dogs showed macroscopic visible hyperaemia of the mucosa and haemorrhagia in the gastrointestinal tract. Microscopic investigations showed extensive changes of the lymphatic tissue indicating an immunosuppression and tubular changes of kidneys and testis, as well as atrophic, necrotic changes of the prostate epithelium.</p><p>Animal studies showed that bendamustine is embryotoxic and teratogenic.</p><p>&nbsp;</p><p>&nbsp;</p><p>Bendamustine induces aberrations of the chromosomes and is mutagenic in-vivo as well as in-vitro. In long-term studies in female mice bendamustine is carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

The powder should be reconstituted immediately after opening of the vial.
The reconstituted concentrate should be diluted immediately with 0.9% sodium chloride solution.

Solution for infusion
After reconstitution and dilution, chemical and physical stability has been demonstrated for 3.5 hours at 25 ºC/ 60%RH and 2 days at 2 ºC to 8 ºC in polyethylene bags.
.
From a microbiological point of view, the solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.</p><p>&nbsp;</p><p>Keep the container in the outer carton in order to protect form light.</p><p>&nbsp;</p><p>For storage conditions of the reconstituted or diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I brown glass vials of 26 ml or 60 ml with rubber stopper and an aluminium flip-off cap.</p><p>&nbsp;</p><p>26 ml-vials contain 25 mg bendamustine hydrochloride and are supplied in packs of 5, 10 and 20 vials. 60 ml-vials contain 100 mg bendamustine hydrochloride and are supplied in packs of 5 vials.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When handling Ribomustin, inhalation, skin contact or contact with mucous membranes should be avoided (wear gloves and protective cloth<u>e</u>s!). Contaminated body parts should be carefully rinsed with water and soap, the eye should be rinsed with physiological saline solution. If possible it is recommended to work on special safety workbenches (laminar flow) with liquid impermeable, absorbing disposable foil. Pregnant personnel should be excluded from handling cytostatics.</p><p>&nbsp;</p><p>&nbsp;</p><p>The powder for concentrate for solution for infusion has to be reconstituted with water for injection, diluted with sodium chloride 9 mg/ml (0.9%) solution for injection and then administered by intravenous infusion. Aseptic technique is to be used.</p><p>&nbsp;</p><p>1.&nbsp; Reconstitution</p><p>Reconstitute each vial of Ribomustin containing 25 mg bendamustine hydrochloride in 10 ml water for injection by shaking;</p><p>Reconstitute each vial of Ribomustin containing 100 mg bendamustine hydrochloride in 40 ml water for injection by shaking.</p><p>The reconstituted concentrate contains 2.5 mg bendamustine hydrochloride per ml and appears as a clear colourless solution.</p><p>&nbsp;</p><p>2.&nbsp; Dilution</p><p>As soon as a clear solution is obtained (usually after 5-10 minutes) dilute the total recommended dose of Ribomustin immediately with 0.9% NaCl solution to produce a final volume of about 500 ml.</p><p>Ribomustin must be diluted with 0.9% NaCl solution and not with any other injectable solution.</p><p>&nbsp;</p><p>&nbsp;</p><p>3.&nbsp; Administration</p><p>The solution is administered by intravenous infusion over 30-60 min.</p><p>&nbsp;</p><p>The vials are for single use only.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Astellas Pharma GmbH Postfach 50 01 66
D-80971 München
Phone: +49 (0)89 45 44 01
Fax: +49 (0)89 45 44 13 29

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02-Aug-2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>